Harmonisation and quantification of PET imaging for lung diseases

1)对研究背景的简要描述，包括潜在的影响每周约有1万人被诊断出患有肺部疾病，在英国，每5分钟就有一人死于这种疾病，占2012年死亡人数的20.1%。非侵入性分子成像技术，如正电子发射断层扫描和计算机断层扫描(PET/CT)，提供了用于开发新的成像生物标志物的功能和结构信息，在诊断肺部异常、评估疾病进展和治疗反应方面发挥着重要作用。然而，由于呼吸运动和组织、空气、血液和水的不同部分的存在，准确量化PET/CT肺成像是具有挑战性的。正电子射程效应以及图像重建和配准方法进一步降低了图像质量。为了应对这些挑战，将开发一种带有组织模拟材料的肺测试对象，以验证现有的组织分数、正电子范围和运动校正方法。2)目的和对象具体目标是提高PET/CT肺部成像的准确性和精密度，并开发标准化的方案，使临床中心之间的测量能够重复进行。这将使使用PET/CT作为药效学终点的多中心治疗疗效临床试验得以进行。3)研究方法的新颖性将研究具有组织模拟特性的新型3D打印材料的生产，用于构建肺测试对象。将进行蒙特卡罗模拟来模拟所设计的几何形状中的辐射传输，并根据该模型对实验测量结果进行验证。4)与EPSRC的战略和研究领域保持一致针对特定应用的测试对象的设计，以优化肺部成像校正的参数，从而实现特定于中心的校正优化。这将有助于多中心临床试验评估疗效的量化标准化。这项工作与EPSRC的医疗保健技术主题相一致，特别是通过优化医学成像来实现“通过有效的诊断、患者特定的预测和基于证据的干预来优化医疗保健”的挑战。5)任何参与国家物理实验室(NPL)葛兰素史克研究与开发有限公司(GSK)的公司或合作者

1) Brief description of the context of the research including potential impactApproximately 10,000 people are diagnosed with a lung disease every week, with one death from the condition every 5 minutes in the UK, accounting for 20.1% of deaths in 2012. Non-invasive molecular imaging techniques such as Positron Emission Tomography and Computed Tomography (PET/CT) provide functional and structural information used to develop novel imaging biomarkers and can play an important role in diagnosing lung abnormalities and assessing disease progression and treatment response. However, accurate quantification of PET/CT lung imaging is challenging due to respiratory motion and the presence of large variations in fractions of tissue, air, blood and water. Image quality is further degraded by positron range effects as well as image reconstruction and registration approaches. To address these challenges, a lung test-object with tissue mimicking materials will be developed to validate existing tissue fraction, positron range and motion correction methods.2) Aims and objectivesThe specific objectives are to improve the accuracy and precision of PET/CT lung imaging and develop standardised protocols to enable reproducible measurements between clinical centres. This would enable multi-centre clinical trials of treatment efficacy to be conducted that use PET/CT as a pharmacodynamic endpoint. 3) Novelty of the research methodologyThe production of novel 3D printing materials with tissue mimicking properties, with which to construct the lung test-object, will be investigated. Monte Carlo simulations will be undertaken to model the radiation transport in the designed geometries, against which the experimental measurements can be validated. 4) Alignment to EPSRC's strategies and research areasThe design of application-specific test-objects to optimise parameters for lung imaging corrections will allow centre-specific correction optimisation. This will aid in standardisation of quantification in multi-centre clinical trials assessing treatment efficacy. This work aligns to the EPSRC's Healthcare technologies theme, specifically the challenge of "Optimising care through effective diagnosis, patient-specific prediction and evidence-based intervention" through optimisation of Medical Imaging.5) Any companies or collaborators involvedNational Physical Laboratory (NPL)GlaxoSmithKline Research & Development Limited (GSK)